CJM-112
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A) . CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways[1].
Product Specifications
UNSPSC
12352203
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
[CJM-112]
References & Citations
[1]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.|[2]Maarouf M, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29 (5) :441-449.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
IL-17
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
21567141 1x 10^6 Cells / 1.0 mL
GKN2 CRISPR Knock Out 293T Cell Line (Human)
Sign In for Pricing
View Details